PARP inhibitors in prostate cancers, is it time for combinations?-Reference-Cited by-同舟云学术

PARP inhibitors in prostate cancers, is it time for combinations?

Published:2024-01 Issue: Volume:16 Page:
ISSN:1758-8359
Container-title:Therapeutic Advances in Medical Oncology
language:en
Short-container-title:Ther Adv Med Oncol

Author:

Teyssonneau Diego¹^ORCID,Dariane Charles²,Barret Eric³,Beauval Jean-Baptiste⁴⁵,Brureau Laurent⁶,Fiard Gaëlle⁷,Fromont Gaëlle⁸,Créhange Gilles⁹,Gauthé Mathieu¹⁰,Ruffion Alain¹¹¹²,Renard-Penna Raphaële¹³,Mathieu Romain¹⁴¹⁵,Sargos Paul¹⁶,Rouprêt Morgan¹⁷,Ploussard Guillaume⁴⁵,Roubaud Guilhem¹⁸

Affiliation:

1. Department of Medical Oncology, Institut Bergonié, 229 Cours de l’Argonne, Bordeaux 33000, France

2. Department of Urology, Hôpital Européen Georges-Pompidou, APHP, Paris University, U1151 Inserm-INEM, Necker, Paris, France

3. Department of Urology, Institut Mutualiste Montsouris, Paris, France

4. Department of Urology, La Croix du Sud Hôpital, Quint Fonsegrives, France

5. IUCT-O, Toulouse, France

6. Department of Urology, CHU de Pointe-à-Pitre, University of Antilles, University of Rennes, Inserm, EHESP, Irset (Institut de Recherche en Santé, Environnement et Travail) – UMR_S 1085, Pointe-à-Pitre, France

7. Department of Urology, Grenoble Alpes University Hospital, Université Grenoble Alpes, CNRS, Grenoble INP, TIMC-IMAG, Grenoble, France

8. Department of Pathology, CHRU Tours, Tours, France

9. Department of Radiation Oncology Curie Institute, Paris, France

10. Department of Nuclear Medicine, Scintep, Grenoble, France

11. Service d’Urologie Centre Hospitalier Lyon Sud, Hospices Civils de Lyon

12. Equipe 2, Centre d’Innovation en Cancérologie de Lyon (EA 3738 CICLY), Faculté de Médecine Lyon Sud, Université Lyon 1, Lyon, France

13. AP-HP, Radiology, Pitie-Salpetriere Hospital, Sorbonne University, Paris, France

14. Department of Urology, University of Rennes, Rennes, France

15. University of Rennes, Inserm, EHESP, Irset (Institut de Recherche en Santé, Environnement et Travail), Rennes, France

16. Department of Radiotherapy, Institut Bergonié, Bordeaux, Aquitaine, France

17. AP-HP, Urology, GRC 5 Predictive Onco-Uro, Pitie-Salpetriere Hospital, Sorbonne University, Paris, France

18. Department of Medical Oncology, Institut Bergonié, Bordeaux, Aquitaine, France

Abstract

Despite several improvements in outcomes, metastatic prostate cancer remains deadly. Alterations in the homologous recombination repair (HRR) pathway are associated with more aggressive disease. Olaparib and rucaparib, two poly-ADP-ribose polymerase (PARP) inhibitors, have received approval from the authorities of several countries for their anti-tumoral effects in patients with metastatic castration-resistant prostate cancers harboring HRR gene alterations, in particular BRCA2. More recently, it has been hypothesized that new hormonal therapies (NHTs) and PARP inhibitors (PARPi) could have synergistic actions and act independently of HRR deficiency. This review proposes to discuss the advantages and disadvantages of PARPi used as monotherapy or in combination with NHTs and whether there is a need for molecular selection.

Publisher

SAGE Publications

Link

https://journals.sagepub.com/doi/pdf/10.1177/17588359241242959

Reference42 articles.

1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

2. Integrative Clinical Genomics of Advanced Prostate Cancer

3. Germline BRCA Mutations Are Associated With Higher Risk of Nodal Involvement, Distant Metastasis, and Poor Survival Outcomes in Prostate Cancer

4. PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer